$11.36
+0.18
(+1.61%)▲
Live
8.54%
Downside
Day's Volatility :8.86%
Upside
0.35%
99.08%
Downside
52 Weeks Volatility :99.7%
Upside
67.03%
Period | Avalo Therapeutics Inc | Index (Russel 2000) |
---|---|---|
3 Months | -11.13% | 0.0% |
6 Months | -8.44% | 0.0% |
1 Year | -61.25% | 0.0% |
3 Years | -99.82% | -23.0% |
Market Capitalization | 102.0M |
Book Value | -$13.16 |
Earnings Per Share (EPS) | -7126.35 |
Wall Street Target Price | 35.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -2751.05% |
Return On Assets TTM | -20.94% |
Return On Equity TTM | -524.01% |
Revenue TTM | 807.0K |
Revenue Per Share TTM | 1.11 |
Quarterly Revenue Growth YOY | -36.3% |
Gross Profit TTM | -7.9M |
EBITDA | -22.1M |
Diluted Eps TTM | -7126.35 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -7.78 |
EPS Estimate Next Year | -6.56 |
EPS Estimate Current Quarter | -6.7 |
EPS Estimate Next Quarter | -8.8 |
What analysts predicted
Upside of 208.1%
Sell
Neutral
Buy
Avalo Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Avalo Therapeutics Inc | 15.62% | -8.44% | -61.25% | -99.82% | -99.87% |
Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Avalo Therapeutics Inc | NA | NA | NA | -7.78 | -5.24 | -0.21 | NA | -13.16 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Avalo Therapeutics Inc | Sell | $102.0M | -99.87% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Avalo Therapeutics Inc
Revenue is up for the last 2 quarters, 236.0K → 571.0K (in $), with an average increase of 58.7% per quarter
Netprofit is up for the last 2 quarters, -121.29M → 98.46M (in $), with an average increase of 223.2% per quarter
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 144.9%
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 144.6%
Logos Global Management LP
Sio Capital Management, LLC
Ikarian Capital, LLC
Affinity Asset Advisors, LLC
COMMODORE CAPITAL LP
Vanguard Group Inc
cerecor inc. is a biopharmaceutical company focused on the discovery, development and commercialization of prescription pharmaceuticals whose primary activity is in the human brain. we are a delaware corporation, organized in april 2011 in partnership with various laboratories and research institutes at johns hopkins medical institute ("jhmi"). cerecor is focused on translational medicine – the accelerated transfer of technology from the academic laboratory to early human trials, with the goal of rapid commercialization. we acquire rights to early stage therapeutic technologies ("assets") from universities, finance and manage the development of these assets into drug candidates (to first major milestone or value inflection point) and then either commercialize or outlicense the asset.
Organization | Avalo Therapeutics Inc |
Employees | 19 |
CEO | Dr. Garry A. Neil M.D. |
Industry | Miscellaneous |
Jpmorgan Betabuilders 1-5 Year Us Aggregate Bd Etf
$11.36
+1.61%
Invesco Bulletshares 2025 Hi
$11.36
+1.61%
Schwab International Dividend Equity Etf
$11.36
+1.61%
Innovator Intl Developed 10 Buffer Etf - Quarterly
$11.36
+1.61%
Lightpath Technologies Inc
$11.36
+1.61%
Vaneck Vectors Global Alternative Energy Etf
$11.36
+1.61%
First Trust Flexible Municipal High Income Etf
$11.36
+1.61%
Drx Dly Reg Bank Bull 3x
$11.36
+1.61%
Graniteshares 2x Long Pltr Daily Etf
$11.36
+1.61%